Navigation Links
Hemostemix Announces Formation of Scientific Advisory Board
Date:6/10/2013

Toronto, Ontario (PRWEB) June 10, 2013

The Hemostemix Group of Companies announced today the formation of its Scientific Advisory Board (the “Board”) and the addition of its first three members.

The Hemostemix Group is comprised of Hemostemix Ltd. (Hemostemix), a company incorporated in Israel with an operating research, development and manufacturing facility in Ness Ziona, Kwalata Trading Ltd. (“Kwalata”), registered in Cyprus, and the parent company Theravitae, Inc. (“TVI”) based in Toronto, Ontario, Canada (collectively the “Hemostemix Group” or “Group”).

The first three members of the Board to be announced are:

Dr. Heinz Redl

Heinz Redl, Ph.D. is the Chair-elect of the European Chapter of the Tissue Engineering and Regenerative Medicine International Society, head of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology and Associate Professor at the Vienna University of Technology. He is coordinator of the Austrian Cluster for Tissue Regeneration (together with the Medical University Vienna) with 5 branches – bone, cartilage, peripheral nerve, soft tissue (wound healing) and imaging - and also the CEO of the non-profit Trauma Care Consult.

Dr. Norman Wong

Norman C.W. Wong, M.D., F.R.C.P.(C) is a Fellow of The Royal College of Physicians of Canada and is currently a Professor in the Departments of Medicine, Biochemistry and Molecular Biology in the Faculty of Medicine at the University of Calgary. His previous roles include Associate VP Research and International, assistant Dean of research for the faculty of Medicine and as well as Director of the Libin Gene Therapy Unit. He has acted as a consultant to several leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories.

Dr. Mark Zucker

Mark Jay Zucker, M.D., J.D., F.A.C.C., F.A.C.P. is Director of the Harvey and Georgina Weinstein National Heart Transplant Center at Newark Beth Israel Medical Center and Clinical Professor of Medicine at the University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, N.J. Dr. Zucker graduated from Northwestern University with his medical degree and from Loyola University with a law degree. Prior to his current appointments, Dr. Zucker has served in faculty positions at Mount Sinai School of Medicine in New York and Loyola University Medical School in Illinois. He currently is Advisory Board Vice-Chair and on the Board of Directors for the New Jersey Organ & Tissue Sharing Network. He has been involved with heart and lung transplantation and mechanical circulatory support for over 25 years and has been a principal or co-investigator on more than 40 trials including trials of cell-based therapies such as the BioHeart myoblast trial and the ongoing Baxter RENEW trial.

“We are committed to having a world-class Scientific Advisory Board we can draw expertise from as we move forward with our strategy and particularly with the phase 2 trial of our cell therapy product for patients with critical limb ischemia recently cleared to proceed by Health Canada,” stated Hemostemix Group President Dr. Valentin Fulga. “Each of the three members announced today has followed our company and its technology for some time and we are very pleased they have agreed to join our SAB,” Fulga concluded.

Further announcements about additions to the Hemostemix Group’s Scientific Advisory Board are expected to be made in the near future.

About Hemostemix Ltd

Hemostemix Ltd is a company incorporated in Israel with an operating research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona. Hemostemix and Kwalata Trading Ltd (“Kwalata”), registered in Cyprus, are wholly-owned subsidiaries of Canadian-based parent company, Theravitae Inc (“TVI”) (collectively, the “Hemostemix Group”).    On 14 May 2013, TVI announced a letter of intent signed with Technical Ventures RX Corp (TSX-V:TIK.P) (“Technical”) regarding a proposed Qualifying Transaction in which Technical would acquire TVI and its subsidiaries in a share transaction. For more information see http://www.hemostemix.com.

Read the full story at http://www.prweb.com/releases/2013Hemostemix/SAB/prweb10807580.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. The Hemostemix Group of Companies Provides Corporate Strategy Update
2. Hemostemix Announces US Patent Allowance
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
8. WuXi PharmaTech Announces Third-Quarter 2011 Results
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Spherix Announces Third Quarter Financial Results
11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... NDA ... former Associate Director of Product Development R&D at Allergan and CMC expert with ... both start-up and established biopharma companies, has joined the firm as an Expert ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Workgroup for Electronic Data ... to create efficiencies in healthcare information exchange and a statutory advisor to the U.S. ... of the federal Office of the National Coordinator for Health Information Technology, will deliver ...
(Date:6/23/2017)... ... June 23, 2017 , ... Biova, LLC., the leader in ... Biova’s Board of Directors. Dr. Henig will bring a wealth of scientific experience in ... as the Chief Technical and Scientific Officer of four major global companies in the ...
(Date:6/23/2017)... ... 23, 2017 , ... Ken Hanson, a medical imaging research scientist at Los ... selected as this year’s recipients of two top awards from SPIE, the international ... other honorees to accept their awards at a banquet in San Diego, California, on ...
Breaking Biology Technology:
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):